A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

Exclusion Criteria

• •prior therapy with PI3K-delta inhibitors（except the intolerable subjects）
• •the dosage of steroid hormone(predisone equivalent) was greater than 20mg/d, and lasted for more than 14 days
• •medical condition of difficulty in swallowing, malabsorption, or other chronic gastrointestinal disease, or conditional that may hamper compliance and/or absorption of the investigational product
• •concurrent drugs which maybe prolong the QT during the study period
• •subjects with central nervous system metastasis
• •Prior or current medical condition of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severe impairment of lung function, etc
• •active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
• •known history of chronic active hepatitis B infection, chronic active hepatitis C
• •known history of immunodeficiency, including HIV positive test, other acquired or congenital immunodeficiency disorders, organ transplantation or allogeneic bone marrow transplantation
• •autologous hematopoietic stem cell transplantation was received within 90 days before the first dose administration
• •pregnancy or breastfeeding
• •prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the participant or impair the assessment of study results
• •receiving granulocyte colony-stimulating factor(GCSF) or blood transfusion within seven days before screening
• •history of a non-lymphoma malignancy except for adequately treated local basal cell carcinoma of the skin and cervical carcinoma in situ
• •subjects, in the opinion of the the Investigator, who are unsuitable to participate in the study for any other reason.